
    
      To measure the long-term changes in weight, plasma lipids and fasting blood glucose after
      switching antipsychotic treatment to aripiprazole, 1 year, open label studies in out and
      in-patients with schizophrenia.

      The measurement of weight and lipid profile and fasting blood glucose will be measured at
      baseline and every 3 months for 1 year.
    
  